Pixelgen Technologies is trying to show researchers something conventional protein measurements often miss: where proteins sit on a cell, which proteins gather together and how those relationships change with disease or treatment. The Stockholm company has built a high-throughput platform for mapping molecular cell architecture at nanoscale resolution, giving scientists another way to understand how individual cells behave across immunology, hematology, oncology and cell therapy.
Pixelgen has now closed an oversubscribed $15.5 million Series B, approximately SEK 150 million, led by Flat Capital, with continued backing from Industrifonden and Navigare Ventures. The funding will accelerate global commercialization of its Proxiome Kit, expand the company into additional markets and support growth across its software, data capabilities and product portfolio.
Founded in 2020, Pixelgen is led by co-founder and CEO Simon Fredriksson, who previously co-founded Olink and helped develop its proximity-based proteomics technology. Co-founder and CTO Filip Karlsson brings experience developing genomic and molecular-analysis products. The company’s broader team combines protein science, computational biology, software and commercial life-sciences expertise.
At the center of Pixelgen’s platform is its Proximity Network Assay, which uses DNA-based readouts to capture how proteins are organized on individual cell surfaces. Instead of relying only on microscopy or measuring protein abundance, the approach can reveal clustering, localization and relationships between proteins across large numbers of cells.
That distinction matters because proteins rarely act independently. Their position and proximity can influence signaling, immune responses and treatment behavior. Pixelgen is effectively adding an architectural layer to single-cell proteomics, helping researchers see not only what proteins are present, but how they are arranged.
The Series B therefore funds more than geographic expansion. Pixelgen is entering the harder phase of proving that molecular architecture can become a routine research dimension alongside genomics and conventional proteomics. If adoption follows, researchers may gain a much richer view of why cells that look similar on paper behave very differently in disease and therapy.
